Antisense oligonucleotides targeting valosin‐containing protein ameliorate muscle pathology and molecular defects in cell and mouse models of multisystem proteinopathy
Clinical and Translational Medicine · 2025
DOI: 10.1002/ctm2.70530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Pallabi Pal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Genetics and Genomic Medicine, University of California, Irvine, California, USA. Hauptthemen laut MEDLINE: Valosin Containing Protein, Oligonucleotides, Antisense. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Cure VCP Disease Inc. Ionis Pharmaceuticals, Inc., Muscular Dystrophy Association.
Abstract (Originalsprache)
Background
Valosin‐containing protein (VCP) related disease, also known as multisystem proteinopathy 1 (MSP1), is an autosomal dominant disease caused by gain‐of‐function pathogenic variants of the VCP gene. The disease presents with variable combinations of inclusion body myopathy, early‐onset Paget's disease of bone, frontotemporal dementia and may also overlap with familial amyotrophic lateral sclerosis. There is currently no treatment for this progressive disease associated with early demise resulting from proximal limb girdle and respiratory muscle weakness. We hypothesise that regulating VCP hyperactivity to normal levels can reduce the disease pathology. Main topics covered In this study, we assessed the effect of antisense oligonucleotides (ASOs) specifically targeting the human VCP gene in the patient (R155H) iPSC‐derived skeletal muscle progenitor cells (SMPCs). ASOs were well tolerated up to a concentration of 5 µM and significantly reduced VCP protein expression in the SMPCs by 48% (95% CI [39–56]). We also treated the transgenic mouse model of VCP disease with the overexpressed humanised VCP severe A232E pathogenic gene variant (VCP A232E mice) with weekly subcutaneous ASO injections starting from 6 months of age for 3 months. In the skeletal muscle of transgenic mice, ASOs resulted in 30% (95% CI [27–32]) knockdown of VCP protein compared with control ASO. The ASO‐mediated reduction of VCP expression in muscle tissue was associated with improvement in autophagy flux and reduction in TAR DNA binding protein 43 (TDP‐43) expression, hallmarks of VCP related MSP1. In addition, ASO‐treated VCP A232E mice showed improvements in functional tests of muscle strength, such as rotarod and inverted screen test compared with mice treated with control ASO.
Conclusions
These results suggest that targeting VCP could be beneficial in preventing the progression of the VCP myopathy and hold promise for the treatment of patients with VCP related MSP1. Key points VCP multisystem proteinopathy 1 is caused by gain‐of‐function pathogenic variants of the VCP gene. VCP targeting ASOs were well tolerated and significantly reduced VCP, TAR DNA binding protein 43 (TDP 43), and autophagy protein expression in the (R155H) iPSC‐derived skeletal muscle progenitor cells (SMPCs). The ASOs reduced VCP, TDP‐43, and autophagy flux expression, and improved functional tests of muscle strength in the humanized VCP A232E mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Genetics and Genomic Medicine, University of California, Irvine, California, USA.
- Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.
- Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, California, USA.
- Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, California, USA.
Förderung
- NCATS NIH HHS
- Cure VCP Disease Inc. Ionis Pharmaceuticals, Inc.
- Muscular Dystrophy Association
Zitieren
APA
Pal, P., Carrer, M., Weiss, L., Jaime, O. G., Cheng, C., Shmara, A., Boock, V., Bosch, D., Youssef, M., Fazeli, Y., Afetian, M., Grossman, T. R., Hicks, M. R., Jafar-Nejad, P., & Kimonis, V. (2025). Antisense oligonucleotides targeting valosin‐containing protein ameliorate muscle pathology and molecular defects in cell and mouse models of multisystem proteinopathy. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70530
Vancouver
Pal P, Carrer M, Weiss L, Jaime OG, Cheng C, Shmara A, et al. Antisense oligonucleotides targeting valosin‐containing protein ameliorate muscle pathology and molecular defects in cell and mouse models of multisystem proteinopathy. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70530
BibTeX
@article{Pal2025,
author = {Pal, Pallabi and Carrer, Michele and Weiss, Lan and Jaime, Olga G and Cheng, Cheng and Shmara, Alyaa and Boock, Victoria and Bosch, Danae and Youssef, Marwan and Fazeli, Yasamin and Afetian, Megan and Grossman, Tamar R and Hicks, Michael R and Jafar-Nejad, Paymaan and Kimonis, Virginia},
title = {Antisense oligonucleotides targeting valosin‐containing protein ameliorate muscle pathology and molecular defects in cell and mouse models of multisystem proteinopathy},
journal = {Clinical and Translational Medicine},
year = {2025},
doi = {10.1002/ctm2.70530}
}
EUVIMED